A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
2018
Abstract
Clear cell kidney cancer is associated with short median overal survival, despite the introduction of vascular endothelial growth factor (VEGF) - targeted therapy a decade ago.These drugs did not achieve a significant overal survival advantqage over prior standards of care in prefviously untreated metastatic disease in the pivotal trials.